Results 101 to 110 of about 1,604,147 (168)
Clinical trial methods for family medicine and primary care. [PDF]
Mash R +3 more
europepmc +1 more source
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang +8 more
wiley +1 more source
Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial.
Janik A +10 more
europepmc +1 more source
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece +18 more
wiley +1 more source
Efficacy and Safety of Seltorexant in Insomnia Disorder: A Randomized Clinical Trial.
Mesens S +8 more
europepmc +1 more source
Survivin and Aurora Kinase A control cell fate decisions during mitosis
Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir +2 more
wiley +1 more source
Smartwatch Use and Physician Well-Being: A Randomized Clinical Trial.
Dyrbye LN +4 more
europepmc +1 more source
Menthol flavour enhances vaping experiences: a randomised crossover clinical trial. [PDF]
Chowdhury S +6 more
europepmc +1 more source
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source

